HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Raffinose

Subscribe to New Research on Raffinose
Share|Follow on Twitter
A trisaccharide occurring in Australian manna (from Eucalyptus spp, Myrtaceae) and in cottonseed meal.
Also Known As:
Gossypose; Melitose; Melitriose; alpha-D-Glucopyranoside, beta-D-fructofuranosyl O-alpha-D-galactopyranosyl-(1-6)-
Networked: 69 relevant articles (7 outcomes, 7 trials/studies) for this Bio-Agent, Comments

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Wutzke, K D: 2 articles (02/2008 - 10/2005)
2. Yamaguchi, Natsu: 2 articles (03/2005 - 08/2004)
3. Watanabe, Jun: 2 articles (03/2005 - 08/2004)
4. Watanabe, Hiroshi: 2 articles (03/2005 - 08/2004)
5. Sonoyama, Kei: 2 articles (03/2005 - 08/2004)
6. Yamaguchi-Shinozaki, Kazuko: 1 article (03/2009)
7. Urano, Kaoru: 1 article (03/2009)
8. Takeda, Migiwa: 1 article (03/2009)
9. Suzuki, Hideyuki: 1 article (03/2009)
10. Shinozaki, Kazuo: 1 article (03/2009)

Related Diseases

1. Flatulence
2. Dehydration (Water Stress)
09/01/1999 - "METHODS: X-ray diffraction, scanning electron microscopy, polarised-light microscopy, differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) were applied to study raffinose pentahydrate and its behaviour during progressive dehydration. "
06/01/2007 - "Mechanically isolated follicles showed higher survival than enzymatically isolated follicles, regardless of periods of exposure to EG or raffinose and subsequent exposure to VS. After 10 days of culture, follicular growth and maturational ability of oocytes derived from vitrified follicles exposed to 2 M EG for 5 min and to VS for 1 min were higher than those from follicles exposed to raffinose solutions for 2-2 min and to VS for 1 min. Histological evaluation revealed that exposure of preantral follicles to raffinose solutions caused cytoplasmic vacuolation in granulosa cells which could be due to cellular shrinkage during dehydration; whereas, exposure to 2 M EG induced morphological alterations in follicles only to a lesser extent."
05/01/2007 - "The progressive conversion of crystalline raffinose pentahydrate to its amorphous form by dehydration at 60 degrees C, well below its melting temperature, was monitored by X-ray powder diffraction over a period of 72 h. "
05/01/2007 - "Assessment of defects and amorphous structure produced in raffinose pentahydrate upon dehydration."
02/01/2005 - "Primary drying of these annealed systems resulted in the dehydration of raffinose pentahydrate to an amorphous phase. "
Order ALL the reference details at left...
3. Eosinophilia
4. Crohn Disease (Crohn's Disease)
04/01/1988 - "1. The relative effects of changes in mucosal surface area and mucosal permeability on the passive uptakes of mannitol and raffinose have been studied in vitro using jejunal biopsies from 48 controls, 32 patients with coeliac disease and 11 patients with Crohn's disease. "
04/01/1988 - "4. In Crohn's disease, permeation of mannitol was reduced by 21%, but that of raffinose and mucosal permeability to both sugars were normal. "
08/01/1990 - "3. In 143 patients with gastrointestinal disease, excretion of both ingested raffinose and lactose was significantly increased in coeliac disease in relapse or in partial remission and in Crohn's disease, but not in the irritable bowel syndrome, coeliac disease in remission or ulcerative colitis. "
08/01/1990 - "The raffinose/L-arabinose excretion ratio, an index of intestinal permeability, was greater than 0.08 in 15/15 untreated coeliac patients but less than 0.06 in all normal subjects and in 9/9 lactase-deficient patients, 15/16 recovered coeliac patients, 5/6 patients with ulcerative colitis, 13/16 patients with Crohn's disease and 61/62 patients with irritable bowel syndrome."
08/01/2003 - "iii) In 40 patients with localized small intestinal damage, Crohn's disease of the ileum (n = 21) and celiac disease with histologically proven duodenal damage (n = 19): the raffinose/mannitol recovery ratio was increased in 100% of patients with celiac disease and in 81% of patients with Crohn's disease; increased lactose/raffinose recovery ratio (hypolactasia) and increased sucrose/raffinose (hyposucrasia) were present in 89% and 95% of celiac patients and 19% and 0% of Crohn's disease patients, respectively. "
Order ALL the reference details at left...
5. Weight Gain

Related Drugs and Biologics

1. Oligosaccharides
2. stachyose
3. Hemoglobins (Hemoglobin)
4. Sucrose (Saccharose)
5. Tannins (Tannic Acid)
6. Protease Inhibitors (Protease Inhibitor)
7. Phytic Acid (Inositol Hexaphosphate)
8. Dextrans (Dextran)
9. Lactose
10. Lactic Acid

Related Therapies and Procedures

1. Resuscitation
2. Ileostomy
3. Oral Administration

blog comments powered by Disqus
TREATMENT OPTIONS
for Flatulence,
Ranking and Evidence
*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.
  • Free Updates for 1 Year
  • All 28 Outcomes
  • Top 200 Key Drugs and Biologics
  • Top 50 Key Therapies and Procedures
  • Detailed History Charts
  • Full Research Evidence References
  • Sample PDF Report on Psoriasis >>
Price:$8.50 USD & Delivery via PDF download
updates for 1 year
Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:
Price:$45.00 USD access via web interface
1 year subscription
Request Bulk Institution License Details >>